GLOBAL DIABETES DRUGS MARKET FORECAST 2019-2027
Global Diabetes Drugs Market is segmented by Diabetes Type( Type 1, Type 2) by Product Class( Insulin (Fast Acting Insulin, Intermediate Acting Insulin, Long-acting Insulin) Non-Insulin (DPP-4 Inhibitor, GLP-1 Receptors Agonists, SGLT-2 Inhibitors)) & by Geography
The significant increase in the Diabetes Drugs market can be attributed to the market growth of both Type 1 and Type 2 Diabetes Drugs market and the increasing rate of occurrence of these diseases. The global diabetes drugs market was valued at $34295 million in 2018 & is estimated to generate net revenue of approximately $60434.87 million by 2027, growing at a CAGR of 6.50% . The base year considered for the study is 2018 and the forecasted period is 2019-2027.
The Diabetes Drugs market is primarily driven by the following factors:
- Increase in the prevalence of diabetes
- Advances in insulin delivery technology
- Growing elderly population
To know more about this report, request a free sample copy
The important driver for the growth in this market is the increase in the prevalence of diabetes which is a result of increasing obesity among people caused by unhealthy diets and sedentary lifestyles. Also, obese individuals are five times more likely to be diagnosed with diabetes than individuals with normal weight. According to research, approximately 13% of the world population is obese, and this increases the risk of developing diabetes, further propelling the market growth. Also, the growing elderly population is influencing the market growth in a big way as the life expectancy rate is rising and the birth rate is declining at the same time. With the increase in the ageing population, the expectancy rate of diabetes is expected to increase with time.
The important challenges faced by both the markets commonly is poor storage conditions and distribution policies for insulin. Insulin is required to be stored at specific conditions to maintain its efficacy, which further increases its cost, especially in low and middle-income countries. Also, there are inadequate distribution policies and a lack of centralized supply chains for insulin which influences the price variations among the countries.
The Diabetes Drugs market segments includes diabetes type and product class.
Diabetes Type is segmented into:
- Type 1
- Type 2
Product Class is segmented into:
- Insulin
- Fast acting insulin
- Intermediate-acting insulin
- Long-acting insulin
- Non-insulin
- DPP-4 inhibitor
- GLP-1 receptors agonists
- SGLT-2 inhibitors
- Other non-insulin drugs
This report covers the present market conditions and the growth prospects of the global diabetes drugs market for 2019-2027 and considered the revenue generated through the sales of diabetes drugs for diabetes type as well as product class to calculate the market size by considering 2017 as the base year.
Geographically, the diabetes drugs market has been segmented on the basis of four major regions, which include:
- Diabetes Drugs North America Market – United States & Canada
- Diabetes Drugs Europe Market – The United Kingdom , France, Germany, Russia , Italy , Denmark, Norway, Austria, Switzerland, Sweden, Netherlands & Rest of Europe
- Diabetes Drugs Asia-Pacific Market – China, India, Australia, Japan, South Korea, Indonesia, Malaysia, Philippines, Thailand, Viet Nam & Rest of APAC
- Rest of World- Latin America & Middle-East and Africa
The Diabetes Drugs market in North America is expected to hold the largest share by 2027 due to the maximum prevalence of diabetic population. The US consumes more than 77% of the total demand for diabetes drugs in the region. The country is followed by Canada. North America has many diabetes drugs manufacturers that offer products for use by both the types (type 1 and type 2) of diabetic patients.
The diabetes drugs market is segmented based on its product class; which are sub-divided into insulin, non-insulin and other emerging products. Insulin is further sub-divided into Fast Acting Insulin, Intermediate Acting Insulin and Long Acting Insulin, while Non-Insulin is further divided into DPP-4 Inhibitor, GLP-1 Receptors Agonists, SGLT-2 Inhibitors and others. Fast-acting insulin gets rapidly absorbed into the bloodstream and is further used to control and correct high blood glucose levels during meals. Intermediate-acting insulin is absorbed slowly as compared to fast-acting insulin and thus controls blood glucose levels overnight, while fasting, and between meals. Long-acting insulin is absorbed slowly into the bloodstream which lasts a day.
The major market players in the global diabetes drugs market are:
- Novo Nordisk A/S
- Sanofi
- Merck
- Eli Lilly And Company
- AstraZeneca
Company Profiles covers analysis of important players.
Novo Nordisk is a global healthcare company engaged in providing diabetes and obesity care products. The company also has a leadership position in haemophilia, growth hormone therapy and hormone replacement therapy. Novo Nordisk operates in Europe, North America, China, Japan, Korea and other regions of the world. It is headquartered in Bagsvaerd, Denmark. Sanofi SA (Sanofi or ‘the group’) is a France-based international pharmaceutical group engaged in research, development, manufacture and marketing of healthcare products. The group classifies its business into two operating segments: Pharmaceuticals, and Human Vaccines. It offers a range of products related to rare diseases, multiple sclerosis, oncology, diabetes, and cardiovascular diseases.
Key Findings of the Global Diabetes Drug market:
- North America holds the largest market share
- Rising prevalence of type 2 diabetes
- Insulin market is anticipated to generate the highest revenue
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP-DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- NORTH AMERICA HOLDS THE LARGEST MARKET SHARE
- RISING PREVALENCE OF TYPE 2 DIABETES
- INSULIN MARKET IS ANTICIPATED TO GENERATE THE HIGHEST REVENUE
- MARKET DETERMINANTS
- MARKET DRIVERS
- INCREASE IN PREVALENCE OF DIABETES
- ADVANCES IN INSULIN TECHNOLOGY
- GROWING ELDERLY POPULATION
- MARKET RESTRAINTS
- STRINGENT REGULATORY CONDITIONS AND GUIDELINES FOR BIOSIMILAR DRUGS
- LACK OF AWARENESS AMONG PEOPLE
- COST SENSITIVITY ISSUES
- MARKET OPPORTUNITIES
- DEVELOPMENT OF NEW FORMULATIONS
- INCREASING RESEARCH AND DEVELOPMENT
- MARKET CHALLENGES
- FIERCE MARKET COMPETITION
- RISING CONCERNS IN SCIENTIFIC COMMUNITY
- GAPS IN NATIONAL-LEVEL DIABETES MANAGEMENT PLANS
- POOR STORAGE CONDITIONS AND DISTRIBUTION POLICIES FOR INSULIN
- MARKET DRIVERS
- MARKET SEGMENTATION
- MARKET BY DIABETES TYPE 2019-2027
- TYPE 1
- TYPE 2
- MARKET BY PRODUCT CLASS 2019-2027
- INSULIN
- FAST ACTING INSULIN
- INTERMEDIATE ACTING INSULIN
- LONG-ACTING INSULIN
- NON-INSULIN
- DPP-4 INHIBITOR
- GLP-1 RECEPTORS AGONISTS
- SGLT-2 INHIBITORS
- OTHER NON-INSULIN DRUGS
- INSULIN
- MARKET BY DIABETES TYPE 2019-2027
- KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTE
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF BUYERS
- THREAT OF COMPETITIVE RIVALRY
- OPPORTUNITY MATRIX
- ETYMOLOGY OF DIABETES DRUGS MARKET
- LEGAL, POLICY AND REGULATORY ISSUES
- PORTER’S FIVE FORCE ANALYSIS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- THE UNITED STATES
- CANADA
- EUROPE
- THE UNITED KINGDOM
- FRANCE
- GERMANY
- RUSSIA
- ITALY
- DENMARK
- NORWAY
- AUSTRIA
- SWITZERLAND
- SWEDEN
- NETHERLANDS
- REST OF EUROPE
- ASIA-PACIFIC (APAC)
- CHINA
- INDIA
- AUSTRALIA
- JAPAN
- SOUTH KOREA
- INDONESIA
- MALAYSIA
- PHILIPPINES
- THAILAND
- VIET NAM
- REST OF ASIA-PACIFIC (ROAPAC)
- REST OF THE WORLD (ROW)
- LATIN AMERICA
- BRAZIL
- MEXICO
- REST OF LATIN AMERICA
- MIDDLE-EAST AND AFRICA
- LATIN AMERICA
- NORTH AMERICA
- COMPANY PROFILES
- ELI LILLY AND COMPANY
- OVERVIEW
- PRODUCTS PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- ASTRAZENECA
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- BRAUN MELSUNGEN AG
- OVERVIEW
- PRODUCT PORTFOLIO
- SCOT ANALYSIS
- STRATEGIC ANALYSIS
- NOVO NORDISK A/S
- OVERVIEW
- PRODUCTS PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- SANOFI
- OVERVIEW
- PRODUCTS PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- DIAVACS INC.
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- XOMA CORP.
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- ALBIREO PHARMA INC.
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- MACROGENICS, INC.
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- ASTELLAS PHARMA
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- GLAXOSMITHKLINE
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- MERCK
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- PFIZER
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- XERIS PHARMACEUTICALS
- OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- ELI LILLY AND COMPANY
LIST OF TABLES
TABLE 1 GLOBAL DIABETES DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 2 GLOBAL DIABETES DRUGS MARKET BY DIABETES TYPES 2019-2027, ($ MILLION)
TABLE 3 GLOBAL DIABETES DRUGS MARKET IN TYPE 1 DIABETES BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 4 GLOBAL DIABETES DRUGS MARKET IN TYPE 2 DIABETES 2019-2027 BY GEOGRAPHY ($ MILLIONS)
TABLE 5 GLOBAL DIABETES DRUGS MARKET BY PRODUCT CLASS 2019-2027 ($ MILLIONS)
TABLE 6 GLOBAL DIABETES DRUGS MARKET IN INSULIN TYPE BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 7 GLOBAL DIABETES DRUGS MARKET IN INSULIN BY TYPES 2019-2027 ($ MILLION)
TABLE 8 GLOBAL INSULIN MARKET IN FAST ACTING INSULIN BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 9 GLOBAL INSULIN MARKET IN INTERMEDIATE ACTING INSULIN BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 10 GLOBAL INSULIN MARKET IN LONG ACTING INSULIN BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 11 GLOBAL DIABETES DRUGS MARKET IN NON-INSULIN DRUGS BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 12 GLOBAL DIABETES DRUGS MARKET IN NON-INSULIN DRUGS BY TYPES 2019-2027 ($ MILLION)
TABLE 13 GLOBAL NON INSULIN DRUGS MARKET IN DPP-4 INHIBITOR BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 14 GLOBAL NON INSULIN DRUGS MARKET IN GLP-1 RECEPTORS AGONISTS BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 15 GLOBAL NON INSULIN DRUGS MARKET IN SGLT-2 INHIBITORS BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 16 GLOBAL NON INSULIN DRUGS MARKET IN OTHER NON INSULIN DRUGS BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 17 GLOBAL DIABETES DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)
TABLE 18 NORTH AMERICA DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 19 EUROPE DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 20 ASIA-PACIFIC DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 21 REST OF THE WORLD DIABETES DRUGS MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 22 LATIN AMERICA DIABETES DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL DIABETES DRUGS MARKET 2019-2027 ($ BILLION)
FIGURE 2 GLOBAL DIABETES DRUGS MARKET, BY TYPE 2 DIABETES 2019-2027 ($ MILLION)
FIGURE 3 AVERAGE LIFE EXPECTANCY AT BIRTH IN 2017, BY CONTINENT AND GENDER (IN YEARS)
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS OF DIABETES DRUGS MARKET
FIGURE 5 THE UNITED STATES DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 6 CANADA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 7 THE UNITED KINGDOM DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 8 FRANCE DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 9 GERMANY DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 10 RUSSIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 11 ITALY DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 12 DENMARK DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 13 NORWAY DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 14 AUSTRIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 15 SWITZERLAND DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 16 SWEDEN DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 17 NETHERLANDS DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 18 REST OF EUROPE DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 19 CHINA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 20 INDIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 21 AUSTRALIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 22 JAPAN DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 23 SOUTH KOREA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 24 INDONESIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 25 MALAYSIA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 26 PHILIPPINES DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 27 THAILAND DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 28 VIETNAM DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 29 REST OF ASIA-PACIFIC DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 30 BRAZIL DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 31 MEXICO DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 32 REST OF LATIN AMERICA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 33 MIDDLE-EAST AND AFRICA DIABETES DRUGS MARKET 2019-2027 ($ MILLION)
- MARKET SEGMENTATION
- MARKET BY DIABETES TYPE 2019-2027
- TYPE 1
- TYPE 2
- MARKET BY PRODUCT CLASS 2019-2027
- INSULIN
- FAST ACTING INSULIN
- INTERMEDIATE ACTING INSULIN
- LONG-ACTING INSULIN
- NON-INSULIN
- DPP-4 INHIBITOR
- GLP-1 RECEPTORS AGONISTS
- SGLT-2 INHIBITORS
- INSULIN
- MARKET BY DIABETES TYPE 2019-2027
- OTHER NON-INSULIN DRUGS GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- THE UNITED STATES
- CANADA
- EUROPE
- THE UNITED KINGDOM
- FRANCE
- GERMANY
- RUSSIA
- ITALY
- DENMARK
- NORWAY
- AUSTRIA
- SWITZERLAND
- SWEDEN
- NETHERLANDS
- REST OF EUROPE
- ASIA-PACIFIC (APAC)
- CHINA
- INDIA
- AUSTRALIA
- JAPAN
- SOUTH KOREA
- INDONESIA
- MALAYSIA
- PHILIPPINES
- THAILAND
- VIET NAM
- REST OF ASIA-PACIFIC (ROAPAC)
- REST OF THE WORLD (ROW)
- LATIN AMERICA
- BRAZIL
- MEXICO
- REST OF LATIN AMERICA
- MIDDLE-EAST AND AFRICA
- LATIN AMERICA
- NORTH AMERICA
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.